PT  - JOURNAL ARTICLE
AU  - Takuva, Simbarashe
AU  - Takalani, Azwidhwi
AU  - Seocharan, Ishen
AU  - Yende-Zuma, Nonhlanhla
AU  - Reddy, Tarylee
AU  - Engelbrecht, Imke
AU  - Faesen, Mark
AU  - Khuto, Kentse
AU  - Whyte, Carmen
AU  - Bailey, Veronique
AU  - Trivella, Valentina
AU  - Peter, Jonathan
AU  - Opie, Jessica
AU  - Louw, Vernon
AU  - Rowji, Pradeep
AU  - Jacobson, Barry
AU  - Groenewald, Pamela
AU  - Dorrington, Rob E.
AU  - Laubscher, Ria
AU  - Bradshaw, Debbie
AU  - Moultrie, Harry
AU  - Fairall, Lara
AU  - Sanne, Ian
AU  - Gail-Bekker, Linda
AU  - Gray, Glenda
AU  - Goga, Ameena
AU  - Garrett, Nigel
AU  - ,
TI  - Safety of the single-dose Ad26.CoV2.S vaccine among healthcare workers in the phase 3b Sisonke study in South Africa
AID  - 10.1101/2021.12.20.21267967
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.20.21267967
4099  - http://medrxiv.org/content/early/2021/12/21/2021.12.20.21267967.short
4100  - http://medrxiv.org/content/early/2021/12/21/2021.12.20.21267967.full
AB  - Background The Sisonke open-label phase 3b implementation study aimed to assess the safety and effectiveness of the Janssen Ad26.CoV2.S vaccine among health care workers (HCWs) in South Africa. Here, we present the safety data.Methods We monitored adverse events (AEs) at vaccination sites, through self-reporting triggered by text messages after vaccination, health care provider reports and by active case finding. The frequency and incidence rate of non-serious and serious AEs were evaluated from day of first vaccination (17 February 2021) until 28 days after the final vaccination (15 June 2021). COVID-19 breakthrough infections, hospitalisations and deaths were ascertained via linkage of the electronic vaccination register with existing national databases.Findings Of 477,234 participants, 10,279 (2.2%) reported AEs, of which 139 (1.4%) were serious. Women reported more AEs than men (2.3% vs. 1.6%). AE reports decreased with increasing age (3.2% for 18–30, 2.1% for 31-45, 1.8% for 46-55 and 1.5% in >55-year-olds). Participants with previous COVID-19 infection reported slightly more AEs (2.6% vs. 2.1%). The commonest reactogenicity events were headache and body aches, followed by injection site pain and fever, and most occurred within 48 hours of vaccination. Two cases of Thrombosis with Thrombocytopenia Syndrome and four cases of Guillain-Barre Syndrome were reported post-vaccination. Serious AEs and AEs of special interest including vascular and nervous system events, immune system disorders and deaths occurred at lower than the expected population rates.Interpretation The single-dose Ad26.CoV2.S vaccine had an acceptable safety profile supporting the continued use of this vaccine in our setting.Funding Funding was provided by the National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation - Grant number 21-V0001, and the Bill & Melinda Gates Foundation – grant number INV-030342.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov number NCT04838795; Pan-African Clinical Trials registry number PACTR202102855526180Funding StatementFunding was provided by the National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation Grant number 21V0001, and the Bill & Melinda Gates Foundation grant number INV030342.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below: South Africa Health Products Regulatory Authority / Ref: 20200465 / Approval 12 February 2021 University of the Witwatersrand Human Research Ethics Committee / Ref: 210217 / Approval 15 February 2021 Pharma Ethics / Ref: 210223848 / Approval 16 February 2021 Sout Africa Medical Research Council Human Research Ethics Committee / Ref: EC006-2/2021 / Approved 12 February 2021 University of KwaZulu Natal Biomedical Research Ethics Committee / Ref: BREC/00002410/2021 Approved 16 February 2021 Sefako Magkato Medical Univeristy Research Ethics Committee / Ref:M/01/2021. Approved 18 February 2021 University of Cape Town Human Research Ethics Committee / Ref: 079/2021. Approved 16 February 2021 Stellenbosch University Human Research Ethics Committee / Ref: 21604. Approved 17 February 2021 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors